Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells

Fig. 4

POG inhibits the proliferation and metabolism of PMN-MDSCs in vitro. a The cytotoxic effect of POG on PMN-MDSCs, CD8 T-lymphocytes and B16-F10 cells. b Effect of POG on the proliferation of PMN-MDSCs, CD8 T-lymphocytes and B16-F10 cells. c Statistical analysis of downregulated biological processes of B16-F10 tumour-bearing PMN-MDSCs after POG treatment. d Statistical analysis of the downregulated molecular function of B16-F10 tumour-bearing PMN-MDSCs after POG treatment. e KEGG analysis of the downregulated genes of B16-F10 tumour-bearing PMN-MDSCs after POG treatment. f GSEA analysis of the downregulated genes of B16-F10 tumour-bearing PMN-MDSCs after POG treatment. g The protein–protein interaction networks of downregulated proteins of B16-F10 tumour-bearing PMN-MDSCs after POG treatment. The pooled data from three independent experiments are shown. All data are represented as the mean ± SD. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page